Breast Biomarker Testing, and What To Do With HER2
Breast biomarker testing has been a routine and standardized part of pathology practice for many decades. With the advent of precision medicine and the introduction of more companion diagnostic assays to guide patient management, pathology laboratories have had to optimize and validate new assays with increasing frequency, often with assay indications evolving during the process. Pathologists, now more than ever, are essential to the patient management team and need to be able to speak to the role of breast biomarker testing as it pertains to treatment decision-making.
Originally published on March 4, 2025
Lecture Presenter
![]() | Laura C. Collins, MD Professor of Pathology |
Dr. Laura C. Collins is the vice chair of Anatomic Pathology and director of Breast Pathology at Beth Israel Deaconess Medical Center (BIDMC) in Boston, Massachusetts. She is a professor of Pathology at Harvard Medical School. Dr. Collins graduated from Charing Cross and Westminster Medical School in London and completed her anatomic and clinical pathology residency training at the Beth Israel Hospital in Boston, followed by a cytopathology fellowship at the same institution (now BIDMC). In 1998, Dr. Collins joined the faculty at BIDMC as a staff pathologist. During her tenure at BIDMC, she has served as the director of the residency training program in anatomic and clinical pathology as well as the director of the selective pathology fellowship training program. Nationally, she has served the United States and Canadian Academy of Pathology (USCAP) as a member of the Education Committee, chair of the Residency Advisory Subcommittee, and most recently, as a member of the USCAP board of directors. She has also served as the president of the Arthur Purdy Stout Society of Surgical Pathologists.
Dr. Collins is an internationally renowned breast pathologist. She has published numerous original articles, review articles, and book chapters on breast pathology. She has twice been the guest editor for a monograph on Current Concepts in Breast Pathology in the Surgical Pathology Clinics Series. She coauthored the popular pathology textbook entitled Biopsy Interpretation of the Breast, which is now in its third edition, and she was a contributor to several chapters in the WHO Classification of Tumours of the Breast, 4th edition, published in 2012, and Breast Tumours: WHO Classification of Tumours, 5th edition, published in 2019.
Her research interests are in breast cancer, and in particular, the understanding of precursor lesions and early breast neoplasia. In addition to her work in research, Dr. Collins is a committed educator, giving numerous lectures and postgraduate CME courses around the U.S. and the world to support the ongoing education of pathologists and pathologists-in-training in the diagnosis of breast disease.
Objectives
After this presentation, participants will be able to:
- Review the current ASCO/CAP biomarker guidelines
- Describe the expected biomarker expression patterns for histologic types and grades of breast cancer
- Discuss the evolving landscape of interpretation of HER2 assays
- Recognize the indications and importance of multigene assays in breast cancer treatment decision making
Sponsored by:
University of Utah School of Medicine, Department of Pathology, and ARUP Laboratories